Baltimore’s BondTrue Awarded Competitive Grant from the National Science Foundation
Small Business Innovation Research Program Provides Seed Funding for R&D
BALTIMORE, Md., March 30, 2021 – BondTrue, LLC (BondTrue) has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000 to conduct research and development (R&D) work on the BondTrue surgical closure device.
BondTrue is a patented, hand-held, disposable device that standardizes the process of surgical closure, which aims to decrease the prevalence of surgical site infections through reduced wound drainage. Additional benefits for improved surgical closure are cost savings to hospitals, surgeon time reallocated to highest skilled tasks and increased patient satisfaction.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, division director of the division of industrial innovation and partnerships, NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”
“The NSF funding and support takes BondTrue through the critical next phase of product development,” said Aimee Martin, CEO. “During this phase, our team will scale up testing, moving this innovative surgical device toward market availability. The goal of BondTrue is to improve patient outcomes and satisfaction, optimize surgical team performance and reduce surgical site infections, which cost the US $3.3 billion annually.”
Receipt of this Phase I SBIR award also means that BondTrue is eligible to apply for a Phase II award (up to $1 million). Small businesses with Phase II funding are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
Startups or entrepreneurs who submit a three-page Project Pitch will know within one month if they meet the program’s objectives to support innovative technologies that show promise of commercial and/or societal impact and involve a level of technical risk. Small businesses with innovative science and technology solutions, and commercial potential are encouraged to apply. All proposals submitted to the NSF SBIR/STTR program, also known as America’s Seed Fund powered by NSF, undergo a rigorous merit-based review process. To learn more about America’s Seed Fund powered by NSF, visit: https://seedfund.nsf.gov/
About the National Science Foundation’s Small Business Programs
America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.5 billion that supports fundamental research and education across all fields of science and engineering.
About BondTrue, LLC
Medical device design and development company. Developed by a surgeon, the BondTrue device standardizes surgical closure for better wound healing. Unlike other closure techniques, BondTrue knows where the incision was made so it may precisely realign the wound back together, reducing wound complications while saving time and costs. https://www.bondtrue.com/
Aimee Martin, CEO
Latest posts by BioBuzz Media (see all)
- Penn cell therapy pioneer Dr. Carl June wins $1M prize - April 15, 2021
- Rockville’s MacroGenics Enters Research Collaboration with Sweden’s Alligator Bioscience to Develop a Novel Immunotherapy - April 15, 2021
- LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases - April 15, 2021
- TEDCO’s Dr. Arti Santhanam: Bringing New Innovations to Market - April 13, 2021
- Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies - April 13, 2021